AbCellera Biologics Inc. ABCL
11.62 USD 0.00 (+0.00%)
At closeNov 13, 2026, 9:14 AM EST
11.97 +0.35 +3.01%
Pre-market · Nov 13, 9:14 AM ET
Day range unavailable
2.75 52-week range 15.02
- YTD
- +239.77%
- 1 year
- +192.70%
News
zacks.com Are Medical Stocks Lagging ABCELLERA BIOLG (ABCL) This Year? Here is how AbCellera Biologics Inc. (ABCL) and Editas Medicine (EDIT) have performed compared to their sector so far this year.
marketbeat.com AbCellera Biologics Eyes Phase 3 for Hot-Flash Drug After Promising Midstage Results AbCellera Biologics NASDAQ: ABCL is preparing to advance its experimental hot-flash treatment ABCL635 into late-stage development next year after a midstage study produced stronger-than-expected…
benzinga.com StoneX Maintains Buy on AbCellera Biologics, Raises Price Target to $15 StoneX analyst Robert Wasserman maintains AbCellera Biologics (NASDAQ:ABCL) with a Buy and raises the price target from $11 to $15.
benzinga.com Stifel Maintains Buy on AbCellera Biologics, Raises Price Target to $14 Stifel analyst Stephen Willey maintains AbCellera Biologics (NASDAQ:ABCL) with a Buy and raises the price target from $9 to $14.
seekingalpha.com AbCellera Biologics Inc. (ABCL) Q3 2026 Earnings Call Transcript AbCellera Biologics Inc. (ABCL) Q3 2026 Earnings Call Transcript
marketbeat.com What AbCellera Biologics (ABCL) Said on Its Q3 Earnings Call AbCellera Biologics NASDAQ: ABCL plans to advance its experimental hot flash treatment ABCL635 into late-stage development in 2027 after reporting positive mid-stage results, while shelving further…
zacks.com AbCellera Biologics Inc. (ABCL) Reports Q3 Loss, Tops Revenue Estimates AbCellera Biologics Inc. (ABCL) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to a loss of $0.19 per share a year ago.
benzinga.com AbCellera Biologics Q3 2026 Earnings Call Transcript AbCellera Biologics (NASDAQ:ABCL) reported third-quarter financial results on Monday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought…- benzinga.com AbCellera Biologics Q3 EPS $(0.13) Beats $(0.16) Estimate, Sales $10.639M Beat $8.416M Estimate AbCellera Biologics (NASDAQ:ABCL) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.16) by 18.75 percent. This is a 31.58 percent increase over losses of…
businesswire.com AbCellera Reports Q3 2026 Business Results VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Reports Q3 2026 Business Results.
benzinga.com UBS Initiates Coverage On AbCellera Biologics with Buy Rating, Announces Price Target of $18 UBS analyst Alice Nettleton initiates coverage on AbCellera Biologics (NASDAQ:ABCL) with a Buy rating and announces Price Target of $18.
benzinga.com JP Morgan Initiates Coverage On AbCellera Biologics with Overweight Rating, Announces Price Target of $17 JP Morgan analyst Brian Cheng initiates coverage on AbCellera Biologics (NASDAQ:ABCL) with a Overweight rating and announces Price Target of $17.- benzinga.com Goldman Sachs Reinstates Neutral on AbCellera Biologics, Announces $13 Price Target Goldman Sachs analyst Andrea Newkirk reinstates AbCellera Biologics (NASDAQ:ABCL) with a Neutral and announces $13 price target.
- benzinga.com AbCellera To Present Phase 2 Data On ABCL635 At IMS 20th World Congress On Menopause AbCellera (NASDAQ:ABCL) today announced an upcoming oral presentation of Phase 2 data on ABCL635 at the International Menopause Society (IMS) 20th World Congress on Menopause, to be held September 30…
benzinga.com What'sGoing On With AbCellera Biologics Stock On Tuesday? AbCellera Biologics stock gains as investors react to Jazz Pharmaceuticals’ FDA approval and the companies’ antibody partnership.
benzinga.com Nayax, Immatics, Moderna, Marvell Technology And Other Big Stocks Moving Higher On Tuesday Nasdaq: NYAX rose 13.9% on Tuesday after announcing acquisition of IPS Group Inc. for $350 million. Other big gainers include CAPR, RZLV, CRML, and MAIR.
benzinga.com What's Going on With AbCellera Biologics Stock On Wednesday? AbCellera shares rise after positive ABCL635 Phase 2 results, while bullish momentum and analyst price targets point to further upside.
benzinga.com National CineMedia Posts Downbeat Q2 Results, Joins Borr Drilling, AbCellera Biologics And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session U.S. stock futures higher, Nasdaq 100 up 150 pts. National CineMedia shares down 16.4% on weak Q2 results and Captivate Holdings acquisition. Other stocks also falling in pre-market trading.- benzinga.com AbCellera Biologics Commences Underwritten Public Offering Of $200M Of Its Common Shares AbCellera Biologics Inc. (NASDAQ:ABCL) ("AbCellera") today announced that it has commenced an underwritten public offering of $200.0 million of its common shares and, in lieu of common shares to…
- benzinga.com Truist Securities Maintains Buy on AbCellera Biologics, Raises Price Target to $30 Truist Securities analyst Robyn Kamaus maintains AbCellera Biologics (NASDAQ:ABCL) with a Buy and raises the price target from $12 to $30.
benzinga.com AbCellera Biologics Menopause Drug Data Shows 'New Efficacy Benchmark' AbCellera reports positive Phase 2 clinical trial results for ABCL635, a single-dose treatment for menopausal hot flashes.
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session Gainers Jin Medical International (NASDAQ:ZJYL) shares rose 58.1% to $3.4 during Monday's regular session. The market value of their outstanding shares is at $16.8 million. As per the press release,…
benzinga.com Varex Imaging Posts Upbeat Q3 Earnings, Joins Bowman Consulting, MarineMax And Other Big Stocks Moving Higher On Monday BWMN gained 55.1%, HZO rose 45.8%, ABCL gained 35.6%, SLN rose 34.3%, ACHR gained 19.5%, NESR gained 16.4%, AQST gained 15.4%, STDN rose 13.7%.
benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session Gainers Jin Medical International (NASDAQ:ZJYL) stock rose 70.7% to $3.67 during Monday's pre-market session. The company's market cap stands at $16.8 million. As per the news, the H1 earnings report…- benzinga.com AbCellera’s ABCL635 Meets Primary Endpoints In Phase 2 Vasomotor Symptom Study Phase 2 results showed best-in-class reductions in both frequency and severity of moderate-to-severe vasomotor symptoms after a single doseABCL635 significantly improved sleep and patient global…
benzinga.com Market-Moving News for August 10th BKYI: -8% | BIO-key And Visualforma Win Contract To Strengthen Digital Identity Security For Portuguese National Security Agency ABCL: 24% | AbCellera Reports Phase 2 Trial Results Showing…- benzinga.com AbCellera Reports Phase 2 Trial Results Showing Significant Symptom Reduction, Improved Sleep, And Favorable Tolerability For ABCL635 Phase 2 results showed best-in-class reductions in both frequency and severity of moderate-to-severe vasomotor symptoms after a single doseABCL635 significantly improved sleep and patient global…
- benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session Gainers AbCellera Biologics (NASDAQ:ABCL) shares increased by 8.2% to $7.5 during Friday's after-market session. The company's market cap stands at $1.9 billion. As per the news, the Q2 earnings…
- benzinga.com AbCellera To Release Top-Line Data From Phase 2 Trial Evaluating ABCL635 For Treatment Of Moderate-To-Severe Vasomotor Symptoms Due To Menopause On August 10 Management to host a conference call and live webcast at 4:30 a.m. PT / 7:30 a.m. ETAbCellera (NASDAQ:ABCL) will release top-line data from its Phase 2 trial evaluating ABCL635 for the treatment of…
- benzinga.com Stifel Maintains Buy on AbCellera Biologics, Raises Price Target to $9 Stifel analyst Stephen Willey maintains AbCellera Biologics (NASDAQ:ABCL) with a Buy and raises the price target from $8 to $9.
benzinga.com Cantor Fitzgerald Maintains Overweight on AbCellera Biologics, Raises Price Target to $12 Cantor Fitzgerald analyst Steve Seedhouse maintains AbCellera Biologics (NASDAQ:ABCL) with a Overweight and raises the price target from $11 to $12.- benzinga.com AbCellera Biologics Q2 EPS $(0.18) Misses $(0.14) Estimate, Sales $4.050M Miss $7.784M Estimate AbCellera Biologics (NASDAQ:ABCL) reported quarterly losses of $(0.18) per share which missed the analyst consensus estimate of $(0.14) by 28.57 percent. This is a 50 percent decrease over losses of…
- benzinga.com Benchmark Upgrades AbCellera Biologics to Buy, Announces $11 Price Target Benchmark analyst Robert Wasserman upgrades AbCellera Biologics (NASDAQ:ABCL) from Hold to Buy and announces $11 price target.
benzinga.com Jazz Pharmaceuticals Gains Oncology Firepower Through AbCellera Collaboration Jazz Pharmaceuticals teams with AbCellera on cancer therapies as analysts maintain positive targets despite a recent Zepzelca trial setback.- benzinga.com Jazz Pharma And AbCellera Announce Preclinical Research Collaboration, Option And License Agreement To Discover, Develop Next-Gen T-Cell Engaging Multispecific Antibodies The collaboration includes $56 million in upfront payments to AbCellera and up to $792 million in potential option fees and milestone payments for any program Jazz exercises its option to developJazz…
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session - benzinga.com AbCellera Biologics Q1 EPS $(0.14) Beats $(0.20) Estimate, Sales $8.315M Beat $5.856M Estimate AbCellera Biologics (NASDAQ:ABCL) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.20) by 30 percent. This is unchanged from the same period last year.…
benzinga.com Earnings Scheduled For May 11, 2026 
benzinga.com Cantor Fitzgerald Initiates Coverage On AbCellera Biologics with Overweight Rating, Announces Price Target of $7 Cantor Fitzgerald analyst Steve Seedhouse initiates coverage on AbCellera Biologics (NASDAQ:ABCL) with a Overweight rating and announces Price Target of $7.- benzinga.com AbCellera To Disclose Interim Results From Phase 1 Portion Of Its Study Of ABCL635, Including Observed Safety Profile, Pharmacokinetic, And Pharmacodynamic Target Engagement Data, During Q1 Earnings Call On May 11 AbCellera (NASDAQ:ABCL) today announced that it will disclose interim results from the Phase 1 portion of its study of ABCL635, including observed safety profile, pharmacokinetic, and pharmacodynamic…
benzinga.com Jones Trading Initiates Coverage On AbCellera Biologics with Buy Rating, Announces Price Target of $11 Jones Trading analyst Debanjana Chatterjee initiates coverage on AbCellera Biologics (NASDAQ:ABCL) with a Buy rating and announces Price Target of $11.
benzinga.com Why Axon Enterprise Shares Are Trading Higher By Over 16%; Here Are 20 Stocks Moving Premarket 
benzinga.com What Sparked AbCellera Biologics To Soar Over 9% After Hours AbCellera Biologics shares jumped 9.3% after hours to $3.52 following an 83% earnings beat in Q4 2025.
benzinga.com AbCellera Biologics Q4 Earnings Report: What Investors Need to Know - benzinga.com AbCellera Biologics Q4 EPS $(0.03) Beats $(0.17) Estimate, Sales $44.900M Beat $6.351M Estimate AbCellera Biologics (NASDAQ:ABCL) reported quarterly losses of $(0.03) per share which beat the analyst consensus estimate of $(0.17) by 82.04 percent. This is a 75 percent increase over losses of…
- benzinga.com Earnings Scheduled For February 24, 2026
benzinga.com AbCellera Biologics's Earnings Outlook 
benzinga.com AbCellera Doses First Participants In Phase 2 Portion Of Its Phase 1/2 Clinical Study For ABCL635 To Treat Moderate-To-Severe Vasomotor Symptoms Associated With Menopause AbCellera (Nasdaq: ABCL) today announced that the first patients have been dosed in the Phase 2 portion of its ongoing Phase 1/2 clinical trial for ABCL635. ABCL635 is a potential first-in-class…- benzinga.com AbCellera Strikes Patent License Deal With Bruker; Bruker To Pay $36M As Future Royalty Payments On Sales Of Beacon Optofluidic Platform Globally AbCellera (Nasdaq: ABCL) today announced that it has entered into a settlement and patent license agreement with Bruker Corporation, resolving the patent litigation between the two companies…
benzinga.com AI Stocks Extend Selloff, Nasdaq 100 Eyes Worst Week Since April: What's Moving Markets Friday? Risk-off sentiment dominated Wall Street on Friday, with selling pressure in AI-linked names intensifying and pushing technology stocks toward their worst week since April.